These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23436301)

  • 21. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
    Marcus RE; Catovsky D; Prentice HG; Newland AC; Chessells JM; Stevens RF; Hann IM; Goldman JM; Hoffbrand AV; Galton DA
    Haematol Blood Transfus; 1987; 30():346-51. PubMed ID: 2442074
    [No Abstract]   [Full Text] [Related]  

  • 22. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
    Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
    Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
    J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
    J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
    Sievers EL; Lange BJ; Alonzo TA; Gerbing RB; Bernstein ID; Smith FO; Arceci RJ; Woods WG; Loken MR
    Blood; 2003 May; 101(9):3398-406. PubMed ID: 12506020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
    Baer MR; George SL; Dodge RK; O'Loughlin KL; Minderman H; Caligiuri MA; Anastasi J; Powell BL; Kolitz JE; Schiffer CA; Bloomfield CD; Larson RA
    Blood; 2002 Aug; 100(4):1224-32. PubMed ID: 12149202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
    Hassler A; Bochennek K; Gilfert J; Perner C; Schöning S; Creutzig U; Reinhardt D; Lehrnbecher T
    Pediatr Blood Cancer; 2016 Jun; 63(6):1070-4. PubMed ID: 26814618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.
    Gibson BE; Webb DK; Howman AJ; De Graaf SS; Harrison CJ; Wheatley K;
    Br J Haematol; 2011 Nov; 155(3):366-76. PubMed ID: 21902686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
    Stevens RF; Hann IM; Wheatley K; Gray RG
    Br J Haematol; 1998 Apr; 101(1):130-40. PubMed ID: 9576193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
    Kolitz JE; George SL; Dodge RK; Hurd DD; Powell BL; Allen SL; Velez-Garcia E; Moore JO; Shea TC; Hoke E; Caligiuri MA; Vardiman JW; Bloomfield CD; Larson RA;
    J Clin Oncol; 2004 Nov; 22(21):4290-301. PubMed ID: 15514371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
    Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
    Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen.
    Bow EJ; Loewen R; Cheang MS; Schacter B
    Clin Infect Dis; 1995 Aug; 21(2):361-9. PubMed ID: 8562745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.
    Sung L; Aplenc R; Alonzo TA; Gerbing RB; Gamis AS;
    Haematologica; 2012 Nov; 97(11):1770-3. PubMed ID: 22801969
    [No Abstract]   [Full Text] [Related]  

  • 38. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
    Lowenthal RM; Bradstock KF; Matthews JP; Bishop JF; Juneja S; Cobcroft R; Eliadis P; Enno A; Gill D; Herrmann RP; Manoharan A; Page FJ; Rooney KF; Rosenfeld D; Seldon M; Taylor KM; Wolf MM; Young GA
    Leuk Lymphoma; 1999 Aug; 34(5-6):501-10. PubMed ID: 10492073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
    Alonzo TA; Kobrinsky NL; Aledo A; Lange BJ; Buxton AB; Woods WG
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):627-35. PubMed ID: 12439034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
    Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.